Avelumab (Anti-PD-L1) in Platinum-Resistant/Refractory Ovarian Cancer: JAVELIN Ovarian 200 Phase III Study Design

References

• Ferlay J , SoerjomataramI, DikshitRet al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN Int. J. Cancer 136(5), e359–e386 (2015).
   PubMed Web of Science ®Google Scholar
• Ledermann JA , RajaFA, FotopoulouCet al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol.24(Suppl. 6), vi24–vi32 (2013).
   PubMed Web of Science ®Google Scholar
• Siegel RL , MillerKD, JemalA. Cancer statistics. CA Cancer J. Clin.67(1), 7–30 (2017).
   PubMed Web of Science ®Google Scholar
• Griffiths RW , ZeeYK, EvansSet al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int. J. Gynecol. Cancer21(1), 58–65 (2011).
   PubMed Web of Science ®Google Scholar
• Wilson MK , Pujade-LauraineE, AokiDet al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann. Oncol.28(4), 727–732 (2017).
   PubMed Web of Science ®Google Scholar
• Herzog TJ , MonkBJ. Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?Gynecol. Oncol. Res. Pract.4, 13 (2017).
   PubMedGoogle Scholar
• Roncolato FT , GibbsE, LeeCKet al. Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Ann. Oncol.28(8), 1849–1855 (2017).
   PubMed Web of Science ®Google Scholar
• Gordon AN , FleagleJT, GuthrieD, ParkinDE, GoreME, LacaveAJ. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol.19(14), 3312–3322 (2001).
   PubMed Web of Science ®Google Scholar
• Monk BJ , HerzogTJ, KayeSBet al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J. Clin. Oncol.28(19), 3107–3114 (2010).
   PubMed Web of Science ®Google Scholar
• Monk BJ , HerzogTJ, KayeSBet al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur. J. Cancer48(15), 2361–2368 (2012).
   PubMed Web of Science ®Google Scholar
• Colombo N , KutarskaE, DimopoulosMet al. Randomized, open-label, Phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J. Clin. Oncol.30(31), 3841–3847 (2012).
   PubMed Web of Science ®Google Scholar
• Lawrie TA , BryantA, CameronA, GrayE, MorrisonJ. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst. Rev. (7), CD006910 (2013).
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E , HilpertF, WeberBet al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized Phase III trial. J. Clin. Oncol.32(13), 1302–1308 (2014).
   PubMed Web of Science ®Google Scholar
• Stockler MR , HilpertF, FriedlanderMet al. Patient-reported outcome results from the open-label Phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J. Clin. Oncol.32(13), 1309–1316 (2014).
   PubMed Web of Science ®Google Scholar
• Oza AM , TinkerAV, OakninAet al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL. Gynecol. Oncol.147(2), 267–275 (2017).
   PubMed Web of Science ®Google Scholar
• Kaufman B , Shapira-FrommerR, SchmutzlerRKet al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol.33(3), 244–250 (2015).
   PubMed Web of Science ®Google Scholar
• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12(4), 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Balar AV , WeberJS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol. Immunother.66(5), 551–564 (2017).
   PubMed Web of Science ®Google Scholar
• Kandalaft LE , PowellDJJr, SinghN, CoukosG. Immunotherapy for ovarian cancer: what’s next?J. Clin. Oncol.29(7), 925–933 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang L , Conejo-GarciaJR, KatsarosDet al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med.348(3), 203–213 (2003).
   PubMed Web of Science ®Google Scholar
• Hwang WT , AdamsSF, TahirovicE, HagemannIS, CoukosG. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol.124(2), 192–198 (2012).
   PubMed Web of Science ®Google Scholar
• Webb JR , MilneK, KroegerDR, NelsonBH. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol. Oncol.141(2), 293–302 (2016).
   PubMed Web of Science ®Google Scholar
• Darb-Esfahani S , KunzeCA, KulbeHet al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget7(2), 1486–1499 (2016).
   PubMedGoogle Scholar
• Gaillard SL , SecordAA, MonkB. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol. Oncol. Res. Pract.3, 11 (2016).
   PubMedGoogle Scholar
• Woo EY , ChuCS, GoletzTJet al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res.61(12), 4766–4772 (2001).
   PubMed Web of Science ®Google Scholar
• Gatalica Z , SnyderC, ManeyTet al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol. Biomarkers Prev.23(12), 2965–2970 (2014).
   PubMed Web of Science ®Google Scholar
• Alexandrov LB , Nik-ZainalS, WedgeDCet al. Signatures of mutational processes in human cancer. Nature500(7463), 415–421 (2013).
   PubMed Web of Science ®Google Scholar
• Chalmers ZR , ConnellyCF, FabrizioDet al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med.9(1), 34 (2017).
   PubMed Web of Science ®Google Scholar
• Goodman AM , KatoS, BazhenovaLet al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther.16(11), 2598–2608 (2017).
   PubMed Web of Science ®Google Scholar
• Zitvogel L , GalluzziL, SmythMJ, KroemerG. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity39(1), 74–88 (2013).
   PubMed Web of Science ®Google Scholar
• Pfirschke C , EngblomC, RickeltSet al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity44(2), 343–354 (2016).
   PubMed Web of Science ®Google Scholar
• Rios-Doria J , DurhamN, WetzelLet al. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. Neoplasia17(8), 661–670 (2015).
   PubMed Web of Science ®Google Scholar
• Heery CR , CoyneGHO, MadanRAet al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J. Clin. Oncol.32(Suppl.), Abstract 3064 (2014).
   Google Scholar
• Boyerinas B , JochemsC, FantiniMet al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol. Res.3(10), 1148–1157 (2015).
   PubMed Web of Science ®Google Scholar
• Heery CR , O’Sullivan-CoyneG, MadanRAet al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a Phase 1a, multicohort, dose-escalation trial. Lancet Oncol.18(5), 587–597 (2017).
   PubMed Web of Science ®Google Scholar
• Shitara K , YamadaY, YohKet al. Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. J. Clin. Oncol.33(Suppl.), Abstract 3023 (2015).
   Google Scholar
• Gulley JL , RajanA, SpigelDRet al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, Phase Ib trial. Lancet Oncol.18, 599–610 (2017).
   PubMed Web of Science ®Google Scholar
• Apolo AB , InfanteJR, BalmanoukianAet al. Avelumab, an anti-PD-L1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, Phase Ib study. J. Clin. Oncol.35(19), 2117–2124 (2017).
   PubMed Web of Science ®Google Scholar
• Chung HC , ArkenauH, WyrwiczLet al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN Solid Tumor Phase Ib trial: analysis of safety and clinical activity. J. Clin. Oncol.34(Suppl.), Abstract 4009 (2016).
   Google Scholar
• Dirix LY , TakacsI, NikolinakosPet al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a Phase Ib JAVELIN solid tumor trial. Cancer Res.76(Suppl. 4), Abstract S1–04 (2016).
   Google Scholar
• Disis ML , PatelM, PantSet al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor Phase Ib trial: safety and clinical activity. J. Clin. Oncol.34(Suppl. 15), Abstract 5533 (2016).
   Web of Science ®Google Scholar
• Kaufman HL , RussellJ, HamidOet al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol.17(10), 1374–1385 (2016).
   PubMed Web of Science ®Google Scholar
• Bavencio (avelumab) injection [package insert]. Darmstadt, Germany: Merck KGaA; 2017.
   Google Scholar
• Bavencio (avelumab) injection [prescribing information (Japan)]. Darmstadt, Germany: Merck KGaA; 2017.
   Google Scholar
• Bavencio (avelumab) injection [summary of product characteristics]. Darmstadt, Germany: Merck KGaA; 2017.
   Google Scholar
• Aaronson NK , AhmedzaiS, BergmanBet al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst.85(5), 365–376 (1993).
   PubMed Web of Science ®Google Scholar
• Greimel E , BottomleyA, CullAet al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur. J. Cancer39(10), 1402–1408 (2003).
   PubMed Web of Science ®Google Scholar
• Herdman M , GudexC, LloydAet al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res.20(10), 1727–1736 (2011).
   PubMed Web of Science ®Google Scholar
• Herzog TJ , AlvarezRD, SecordAet al. SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. Gynecol. Oncol.135(1), 3–7 (2014).
   PubMed Web of Science ®Google Scholar
• Broglio KR , BerryDA. Detecting an overall survival benefit that is derived from progression-free survival. J. Natl Cancer Inst.101(23), 1642–1649 (2009).
   PubMed Web of Science ®Google Scholar
• Herzog TJ , IsonG, AlvarezRDet al. FDA ovarian cancer clinical trial end points workshop: a Society of Gynecologic Oncology white paper. Gynecol. Oncol.147(1), 3–10 (2017).
   PubMed Web of Science ®Google Scholar